FRISCO, Texas — Soleo Health, an innovative leader and national provider of complex specialty pharmacy services, announced today it has been selected by Eisai Inc., a developer of pharmaceuticals, as the sole specialty pharmacy distribution partner for newly U.S. Food & Drug Administration (FDA)-approved LEQEMBI (lecanemab-irmb) for the treatment of Alzheimer’s Disease (AD). LEQEMBI, an anti-amyloid monoclonal antibody used to treat mild cognitive impairment (MCI) due to AD and mild AD (collectively known as early AD), was approved by the FDA on January 6, 2023.
Patients receiving LEQEMBI will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center (TCMC), staffed with specially trained interdisciplinary teams comprising highly experienced physician specialists, nurse practitioners, therapy-care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. Soleo Health’s distinctive Alzheimer’s Disease TCMC is supported through the Company’s specialty pharmacy locations nationwide with pharmacy licensure in all 50 states.
Soleo Health will distribute LEQEMBI to provider offices and infusion centers as well as administer it across its many Ambulatory Infusions Centers (AICs) nationwide, including those owned and operated through its provider division, Virtis Health. The combined service offering of Soleo Health and Virtis Health provides patients with flexible site of care options to meet their individual therapy needs and service expectations in a cost-effective setting.
“The selection of Soleo Health as the sole specialty pharmacy distributor for LEQEMBI reflects confidence in our clinical expertise and differentiated patient care model supporting patients in the neurology space. Our partnership with Eisai will afford the Alzheimer’s community continued hope while we assist patients and their caregivers as they navigate their healthcare journey,” said Drew Walk, Soleo Health Chief Executive Officer.
Comments are closed.